Table 3.

Factors Associated with ADMA in HIV Infection

Parameter	Unadjusted Estimate (95% CI), p-value	Adjusted Estimate (95% CI), p-value
Age (per decade)	−0.00098 (−0.013, 0.011), p=0.87	−0.0019 (−0.014, 0.010), p=0.75
Female vs. Male	0.041 (0.0095, 0.073), p=0.011	0.047 (0.014, 0.081), p=0.0057
African-American vs. Caucasian	0.0042 (−0.020, 0.029), p=0.74	−0.018 (−0.044, 0.0079), p=0.17
Other/Latino vs. Caucasian	−0.011 (−0.044, 0.022), p=0.52	−0.011 (−0.043, 0.022), p=0.52
Pack Years (per 10 yr increase)	0.0071 (0.00077, 0.014), p=0.028	0.0072 (0.00083, 0.014), p=0.027
VL > 75 vs. VL ≤ 75 (copies/mL)	0.037 (0.014, 0.061), p=0.0017	0.035 (0.011, 0.058), p=0.0045
Current CD4+ (cells/μL per doubling)	−0.015 (−0.028, −0.0020), p=0.024	−0.014 (−0.027, −0.0011), p=0.033

^*Analysis includes all 248 HIV-infected participants

^†Abbreviations: ADMA, asymmetric dimethylarginine; CI, confidence interval; VL, viral load.